HomeCompareMKGAF vs SBUX

MKGAF vs SBUX: Dividend Comparison 2026

MKGAF yields 2.04% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $19.3K in total portfolio value
10 years
MKGAF
MKGAF
● Live price
2.04%
Share price
$122.45
Annual div
$2.50
5Y div CAGR
52.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$138.2K
Annual income
$57,634.11
Full MKGAF calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — MKGAF vs SBUX

📍 SBUX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMKGAFSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MKGAF + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MKGAF pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MKGAF
Annual income on $10K today (after 15% tax)
$173.61/yr
After 10yr DRIP, annual income (after tax)
$48,988.99/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, SBUX beats the other by $6,975.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MKGAF + SBUX for your $10,000?

MKGAF: 50%SBUX: 50%
100% SBUX50/50100% MKGAF
Portfolio after 10yr
$147.8K
Annual income
$61,737.12/yr
Blended yield
41.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

MKGAF
No analyst data
Altman Z
2.6
Piotroski
5/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MKGAF buys
0
SBUX buys
0
No recent congressional trades found for MKGAF or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMKGAFSBUX
Forward yield2.04%2.75%
Annual dividend / share$2.50$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.7%48.3%
Portfolio after 10y$138.2K$157.5K
Annual income after 10y$57,634.11$65,840.13
Total dividends collected$109.9K$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary

Year-by-year: MKGAF vs SBUX ($10,000, DRIP)

YearMKGAF PortfolioMKGAF Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,012$311.88$11,107$407.21$95.00SBUX
2$12,273$490.13$12,512$626.87$239.00SBUX
3$13,912$779.56$14,366$978.69$454.00SBUX
4$16,146$1,261.05$16,929$1,557.50$783.00SBUX
5$19,365$2,088.77$20,658$2,543.80$1.3KSBUX
6$24,296$3,575.17$26,406$4,302.22$2.1KSBUX
7$32,398$6,401.21$35,877$7,622.00$3.5KSBUX
8$46,847$12,181.47$52,741$14,352.64$5.9KSBUX
9$75,264$25,137.47$85,676$29,243.03$10.4KSBUX
10$138,167$57,634.11$157,513$65,840.13$19.3KSBUX

MKGAF vs SBUX: Complete Analysis 2026

MKGAFStock

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment also provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. The Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.

Full MKGAF Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this MKGAF vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MKGAF vs SCHDMKGAF vs JEPIMKGAF vs OMKGAF vs KOMKGAF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.